Waveguide near-eye displays (NEDs) consist of a planar waveguide combiner and a coupling-in projection system. A two-dimensional geometrical waveguide (TDGW) can achieve an ultra-thin, large exit pupil diameter (XPD), wide-angle NED. The design method of a single-layer TDGW is presented and discussed in detail in this paper. A high-precision processing technology that can effectively guarantee the parallelism accuracy is also presented. A miniature coupling-in projection optics is designed with a catadioptric structure and integrated with the waveguide accordingly. Finally, a TDGW with a thickness of 1.75 mm is designed and analyzed. The results show that the stray light over the normal light is less than 0.5%, and the illuminance uniformity is well optimized. The field of view is up to 55°, and the XPD exceeds 12×10 at an eye relief (ERF) of 18 mm. A proof-of-concept prototype was fabricated and demonstrated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1364/AO.459644 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pivotal trial characteristics and types of endpoints used to support Food and Drug Administration rare disease drug approvals between 2013 and 2022.
Clin Trials
January 2025
Rare Diseases Team, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Background/aims: Rare disease drug development faces unique challenges, such as genotypic and phenotypic heterogeneity within small patient populations and a lack of established outcome measures for conditions without previously successful drug development programs. These challenges complicate the process of selecting the appropriate trial endpoints and conducting clinical trials in rare diseases. In this descriptive study, we examined novel drug approvals for non-oncologic rare diseases by the U.
View Article and Find Full Text PDFAdaptive promising zone design for sequential parallel comparison design with continuous outcomes.
Clin Trials
January 2025
Department of Biostatistics, University of Florida, Gainesville, FL, USA.
Introduction: The sequential parallel comparison design has emerged as a valuable tool in clinical trials with high placebo response rates. To further enhance its efficiency and effectiveness, adaptive strategies, such as sample size adjustment and allocation ratio modification can be employed.
Methods: We compared the performance of Jennison and Turnbull's method and the Promising Zone approach for sample size adjustment in a two-phase sequential parallel comparison design study.
Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia.
Front Biosci (Landmark Ed)
January 2025
Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China.
Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use.
View Article and Find Full Text PDFDesign and early progress of the Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial.
Int J Stroke
January 2025
Medical University of South Carolina, Charleston, SC, USA.
Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.
Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.
Reconstruction of anterior talofibular ligament and posterior tibiotalar ligament enhance ankle stability after total talus replacement by finite element analysis.
Comput Methods Biomech Biomed Engin
January 2025
Key Laboratory of Advanced Design and Simulation Techniques for Special Equipment, Ministry of Education, Hunan University, Changsha, China.
Total talus replacement has been demonstrated to increase ankle instability. However, no studies have explored how to enhance postoperative stability. This study aims to explore the effect of collateral ligament reconstruction on ankle stability by finite element analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!